Interview with Aitor Alapont, CEO of P4Q Health: “With the support of CDTI Innovación, we are bringing reproductive hormone diagnostics into the home environment”
P4Q Health, the health unit of the Kinematics group, is developing—driven by CDTI Innovación—a digital platform for the detection of female reproductive hormones that enables home-based monitoring with clinical precision and real-time results.
Digitalisation is profoundly transforming healthcare, opening the door to more accessible, personalised, and patient-centred models. In this context, female reproductive health represents one of the areas with the greatest potential for innovation, particularly in terms of access to reliable information and the possibility of continuous monitoring outside the clinical environment.
Within this framework, the PT FERT project was created, led by P4Q Health—the health-focused unit of the Kinematics group, formerly known as P4Q—with the support of CDTI Innovation. The project is focused on developing a digital platform for the detection of female reproductive hormones in the home environment, while maintaining clinical-grade accuracy standards.
The aim of the project is to bring tests that have traditionally been restricted to clinical settings into the home environment, facilitating fast and simple access to reliable information on reproductive health.
From industrial technology to personalised healthcare
The project builds on the technological track record of the Kinematics group, which has expertise in advanced electronics, IoT, and cloud data analytics—capabilities that have been key to the development of the platform within the PT FERT project.
On this foundation, the company has evolved into the biomedical field with a clear objective: to transfer this knowledge into solutions with a direct impact on people’s lives. “From the beginning, we have had a clear purpose: to develop technology centred on people, capable of improving their daily lives and generating real, tangible impact,” explains Aitor Alapont, CEO of P4Q Health.
This vision translates into the development of a digital ecosystem that enables users to better understand their health status and make informed decisions, moving towards a more preventive and personalised model.
Female health at the centre of innovation
The origin of the project is directly linked to a need identified in the field of women’s health. Based on technologies already developed by the company for biomarker measurement, the team identified the potential to apply these solutions to hormonal monitoring.
The initiative emerged after observing, through contact with patients, healthcare professionals, and its network of collaborators, a growing interest in tools that allow closer monitoring of hormone levels throughout different stages of the life cycle. “This initiative was born with a very clear objective: to offer women something essential and often undervalued in healthcare—peace of mind,” says Alapont.
The project therefore responds not only to a technological challenge but also to the need to move towards more inclusive and personalised care models, reinforcing the role of innovation in improving women’s health.
A digital ecosystem for at-home diagnostics
As part of the PT FERT project, P4Q Health is developing a digital platform that integrates different technological components into a single solution: a digital reader with a spectrometric sensor, immunofluorescence-based tests, and a mobile application that allows users to view and interpret results. “This ecosystem enables accurate and reliable measurements within minutes, providing an agile diagnostic experience for both healthcare professionals and patients,” explains the CEO.
The system delivers quantitative results in a matter of minutes, facilitating both patient use and clinical decision-making, bringing laboratory-level capabilities into the home environment.
This advancement is aligned with the Sustainable Development Goals (SDGs), specifically SDG 3: Good Health and Well-being, by enabling faster, more accessible, and more patient-centred diagnostic tools.
Innovation to overcome technical challenges
One of the main challenges of the PT FERT project has been adapting hormonal analysis to capillary blood samples, a more complex environment than traditional laboratory settings. “The tests need to be adapted to make them compatible with blood samples. In optical-based systems, the quality of the signal obtained is especially important,” explains Alapont.
In addition, there is a need to minimise sample volume to enable home use, which requires optimising detection systems. “Reducing sample volume makes detection of the target analyte more challenging,” he adds.
This continuous improvement process, based on iterative design and validation cycles, reflects the R&D-intensive nature of the project.
Designing with the user in mind
Beyond technology, user experience has been a core pillar of the development. The company has worked directly with patients to adapt the solution to real needs. “Usability is a key aspect in the development of these solutions. It is not enough for the technology to work; it must be easy to use, understandable, and inspire trust,” highlights the CEO.
In this regard, the team has continuously refined both the device and the application to ensure an intuitive experience. “We rely heavily on user feedback. That is what allows us to improve and truly align with what they need,” he explains.
International collaboration and scientific development
The project also involves collaboration with Sun Yat-sen University, a leading institution in biomedical research. “Our partners in China contribute to the design of immunoassays, bringing their extensive industry experience,” explains Alapont.
The combination of industrial, technological, and scientific capabilities enables a multidisciplinary approach to development.
Impact on patients and healthcare professionals
The solution developed by P4Q Health within PT FERT has a direct impact on both patients and healthcare professionals. In the words of the CEO: “Our solution allows patients to access quantitative information in real time, significantly reducing waiting times that, in many cases, generate uncertainty and anxiety.”
In addition, the less invasive nature of the test enables more frequent use, supporting continuous monitoring. From a clinical perspective, the immediate availability of quantitative data helps optimise decision-making and reduces dependence on external laboratories.
The role of CDTI Innovación
The development of PT FERT has been supported by CDTI Innovación, whose role has been key in driving the initiative forward. “CDTI’s support has been a key element for the scalability of the project,” emphasises Alapont, adding: “It has allowed us to strengthen our talent structure and accelerate development, validation, and industrialisation of the solution.”
In this sense, CDTI acts as a catalyst for innovation, helping to promote technological projects with a societal impact.
The future: data, prevention and autonomy
Looking ahead, P4Q Health will continue developing solutions that place the patient at the centre of the healthcare system, with initiatives such as the PT FERT project aimed at improving access to reliable information and enabling more continuous and personalised health monitoring.
“The future of P4Q Health is very clear: to empower people to regain sovereignty over their own health,” concludes Alapont.
In this sense, the development of platforms such as PT FERT marks a step forward towards more preventive, accessible, and data-driven healthcare models, where diagnostics become naturally integrated into patients’ daily lives.
Image: P4Q Health facilities, where advanced technological solutions in the field of healthcare are developed
CDTI Innovación
The Centre for the Development of Industrial Technology and Innovation (CDTI E.P.E.) is the innovation agency of the Spanish Ministry of Science, Innovation and Universities, responsible for promoting technological innovation in the business sector. CDTI’s mission is to ensure that Spain’s business ecosystem generates and transforms scientific and technical knowledge into globally competitive, sustainable, and inclusive growth. In 2025, within the framework of its 2024–2027 Strategic Plan, CDTI provided more than €2 billion in support to Spanish companies and startups.
More information:
Web: www.cdti.es
Linkedin: https://www.linkedin.com/company/29815
X: https://x.com/CDTI_innovacion
Youtube: https://www.youtube.com/user/CDTIoficial
cloud technology axon
Addleshaw Goddard (AG), the London-headquartered international law fir...
